Find a Clinical Trial

Showing 61 - 70 of 179 Trials

A pilot feasibility and efficacy (phase 2) trial of real time drug screening and genomic testing to determine an individualized treatment plan in children and young adults with relapsed medulloblastoma and ependymoma

Principal Investigator:

James H Garvin Jr, MD

Contact Number:

212-342-5162

NCT Number:

NCT05057702

Population:

Pediatrics/Adult

Phase:

II

The purpose of this single armed multi-center pilot trial is to allow every child and young adult with relapsed medulloblastoma to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer. The study will test the feasibility of performing real-time drug screening on tissue taken during surgery, and of having a specialized tumor board assign an individualized treatment...
A phase II single-arm study of cemiplimab, added to typical chemotherapy(gemcitabine, cisplatin, nab-paclitaxel) for down-staging of locally advanced, unresectablebiliary tract cancer

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

Population:

Adult

Phase:

II

The purpose of this study is to combine chemotherapy that has previously been shown to have activity in patients with biliary tract cancer with a drug that stimulates the body’s immune system against cancer cells (immunotherapy). Previously, the combination of gemcitabine and cisplatin with immunotherapy has been shown to prolong life in patients with advanced biliary tract cancer. Adding nab-paclitaxel, another chemotherapy, to gemcitabine and cisplatin, has also been shown to prolong life in some patients with advanced biliary tract cancer. However, all four of these drugs have not...
A Phase 3, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in participants with isocitrate dehydrogenase 1 (IDH1)-mutant glioma

Principal Investigator:

Andrew B. Lassman, MD, FAAN, FASCO

Contact Number:

212-342-5162

NCT Number:

NCT05303519

Population:

Adult

Phase:

II

The purpose of this study is to see how safe and effective Safusidenib erbumine, the study drug, is in treating brain glioma and to find the recommended dose of the study drug for clinical studies. Safusidenib is not Food and Drug Administration (FDA) approved. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must have have life expectancy 3 months or more - Must have negative result for COVID
A phase 2 study of fixed therapy with pirtobrutinib and obinutuzumab in previously untreated chronic lymphocytic leukemia (POP)

Principal Investigator:

Andrew H Lipsky, MD

Contact Number:

212-342-5162

NCT Number:

NCT06333262

Population:

Adult

Phase:

II

The purpose of this study is to learn about possible initial treatments for chronic lymphocytic leukemia (CLL). This study will evaluate the investigational drug pirtobrutinib in combination with the commercially available drug obinutuzumab to treat CLL. The U.S. Food and Drug Administration (FDA) has approved pirtobrutinib for the treatment of CLL that has returned (relapsed) or is resistant to other treatments. Pirtobrutinib i is not FDA approved for the first-time treatment of CLL. The FDA has approved obinutuzumab for the Are you Eligible? (Inclusion Criteria) Must be ≥18 years of age...
A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination with Temozolomide in Patients with Newly Diagnosed Glioblastoma with Unmethylated MGMT Promoter and EGFRvIII

Principal Investigator:

Peter Chei-Way Pan, MD

Contact Number:

212-342-5162

NCT Number:

NCT07326566

Population:

Adult

Phase:

II

The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat cancer better than using temozolomide alone. Silevertinib has not been approved by the Food and Drug Administration (FDA). Temozolomide is FDA approved but not in combination with silevertinib. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Cannot have major surgery within 4 weeks before first dose of study drug or scheduled for surgery during the study - Cannot have poorly controlled gastrointestinal disorders that may interfere with absorption of...
A Phase 2 Multicenter Study of TL-895 in Subjects withMyelofibrosis, Indolent Systemic Mastocytosis, MonoclonalMast Cell Activation Syndrome, or Non-Monoclonal Mast CellActivation Syndrome

Principal Investigator:

Joseph G. Jurcic, MD

Contact Number:

212-342-5162

NCT Number:

NCT04655118

Population:

Adult

Phase:

II

The purpose of this study is to evaluate whether the investigational drug TL-895, which has not been approved by the U.S. Food and Drug Administration (FDA), can help improve symptoms in people with indolent systemic mastocytosis (ISM). TL-895 is being studied alone, in combination with avapritinib, and in comparison with either placebo or avapritinib. Avapritinib is an approved drug that is already used to treat certain types of systemic mastocytosis. A placebo is a treatment with no active therapeutic effect, used to compare against an investigational drug. The main goals of the study are...
A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT06368817

Population:

Pediatrics/Adult

Phase:

II

The purpose of the study is to see how well a lower dose radiotherapy after chemotherapy treats children with central nervous system germinomas. The primary objective is to determine whether 12 Gy whole ventricular irradiation (WVI) and 12 Gy tumor boost would maintain similar efficacy compared to ACNS1123 stratum 2 as measured by event-free survival (EFS) in eligible patients with localized primary central nervous system (CNS) germinoma who present with serum and/or CSF human chorionic gonadotropin-beta (hCGβ) ≤ 100 IU/L and normal AFP, and meet complete response (CR) or continued...
A phase 2, randomized, open-label study of gemcitabine/cisplatin plus cemiplimab (REGN2810, anti-PD-1) with or without fianlimab (REGN3767, anti-LAG-3) for organ preservation in patients with localized muscle-invasive bladder cancer (NeoSTOP-IT)

Principal Investigator:

Alexander Z. Wei, MD

Contact Number:

212-342-5162

NCT Number:

NCT06571708

Population:

Adult

Phase:

II

This study is for patients with a localized bladder cancer called muscle-invasive bladder cancer. Muscle-invasive bladder cancer is usually treated with a combination of chemotherapy and surgery. This surgery removes the entire bladder, which changes how they urinate for the rest of their life. Some patients will have a small opening in the skin of their abdomen where urine will leave their body and go into a bag (this is called an ileal conduit). The goal of this study is to see if we can find ways of sparing patients from having to undergo this surgery. In this study, they will first...
A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA

Principal Investigator:

Gulam A. Manji, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT05968326

Population:

Adult

Phase:

II

The purpose of this study is to compare the effects, good or bad, of autogene cevumeran plus atezolizumab and mFOLFIRINOX compared with mFOLFIRINOX (standard of care chemotherapy) alone on patients with resected pancreatic ductal adenocarcinoma (PDAC). In this study, the participant will get either the combination of autogene cevumeran plus atezolizumab and mFOLFIRINOX or mFOLFIRINOX alone. Autogene cevumeran is a personalized drug product that will be made specifically for the participant and is designed to activate and train your immune system to find and kill cancer cells. Autogene...
Cascade Testing In Racially/Ethnically Diverse Relatives of Patients with Breast or Ovarian Cancer (CASSIE)

Principal Investigator:

Alissa Michel, MD

Contact Number:

212-342-5162

Population:

Adult

Phase:

II

The study is being done to answer the following question: How can we best help women with family members who have cancer and a genetic mutation in a cancer gene make decisions about undergoing genetic testing? We are doing this study because we want to better understand if our web-based tool, RealRisks, can help women with family members who have a genetic variant make an informed decision about genetic testing. Are you Eligible? (Inclusion Criteria) 18 years or older. - Both men and women of all races and ethnic groups are eligible as probands for this trial. Only female first-degree...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

Population:

Phase:

Pages